Proteomics International Laboratories (ASX:PIQ) has secured a United States patent for PromarkerEndo, its proprietary blood test for diagnosing endometriosis, a development the company describes as a major step toward global commercialisation.
The US Patent and Trademark Office granted the patent titled Endometriosis Biomarkers under US Patent No. 12674806, providing intellectual property protection in the world’s largest healthcare market and strengthening the company’s patent portfolio.
The granted claim covers methods for diagnosing endometriosis by measuring specific protein biomarkers in blood and using those results to guide treatment selection.
Proteomics International said the protection is expected to extend until March 2041, subject to grant and maintenance requirements.
The company said that published clinical studies have shown high accuracy for PromarkerEndo in detecting endometriosis, including early-stage disease, and that patent protection has already been secured in Japan and is being pursued in other key jurisdictions such as Australia, Canada, China, Europe, India, Singapore and South Korea.
Endometriosis affects about one in nine women and girls and is commonly diagnosed by surgical laparoscopy, with diagnosis typically taking an average of seven years. PromarkerEndo is built on the company’s Promarker biomarker discovery platform, which identifies protein fingerprints in blood to distinguish people who have a disease from those who do not, offering a non-invasive alternative to current diagnostic methods.
Proteomics International CEO and Managing Director Mr David Morris said, “The grant of this patent by the USPTO is a major achievement and an important validation of the novelty and commercial potential of PromarkerEndo. The United States is the world’s largest healthcare market and securing patent protection in this jurisdiction is a critical step in our global commercialisation strategy. This milestone significantly strengthens our position for future partnerships, licensing discussions, and regulatory reimbursement advancement.”
